Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

BACKGROUND: Ipilimumab is a monoclonal antibody that antagonizes cytotoxic T lymphocyte antigen-4, a negative regulator of the immune system. The authors report on advanced refractory melanoma patients treated in a compassionate use trial of ipilimumab at the Memorial Sloan-Kettering Cancer Center....

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Geoffrey Y, Yuan, Jianda, Page, David B, Schroeder, Sebastian E A, Panageas, Katherine S, Carvajal, Richard D, Chapman, Paul B, Schwartz, Gary K, Allison, James P, Wolchok, Jedd D
Formato: Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917065/
https://www.ncbi.nlm.nih.gov/pubmed/20143434
http://dx.doi.org/10.1002/cncr.24951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917065/
https://www.ncbi.nlm.nih.gov/pubmed/20143434
http://dx.doi.org/10.1002/cncr.24951

Ejemplares similares